



Press Release

Thursday, May 10, 2012



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR ACETAZOLAMIDE INJECTION, USP

- *Product to be launched shortly*
-

May 10, 2012, Bangalore: Strides Arcolab Limited (Strides) today announced that it has received ANDA approval from US FDA for *Acetazolamide for Injection USP, 500 mg/ vial* (preservative free) in lyophilized format.

According to IMS, the 2011 U.S. market for Injectable Acetazolamide approximates to USD 10 Million with only one active player. The product is expected to be launched shortly.


Acetazolamide is the fourteenth product approved under the Sagent - Strides partnership. Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent

About Acetazolamide

Acetazolamide, is used for adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

About Agila Specialties

Agila, Specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencyllins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 9 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.



About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<p><u>Strides</u></p> <p>Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111</p> <p>Mr. Ajay Singh : +91 80 6784 0813 Mr. Kannan N : +91 98450 54745 (Investors)</p>	<p><u>PR Consultancy</u></p> <p>Corporate Voice Weber Shandwick Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in</p> <p>Kaveri Mandanna, +91 90089 59697 kaveri@corvoshandwick.co.in</p>
---	--

